Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.47 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143959 | 1.00 | MAPK13 (0.48) | MAPK13RAF1MAPK12MAPK11MAPK14 | |
| SCHEMBL8118629 | 0.87 | GABRG2 (0.51) | MAPK13RAF1MAPK12MAPK11MAPK14 | |
| SCHEMBL7141999 | 0.86 | IDO1 (0.51) | ALDH1A3GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL27544569 | 0.84 | GABRG2 (0.51) | ALDH1A3GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7139559 | 0.84 | HPGDS (0.43) | MAPK13RAF1MAPK12MAPK11MAPK14 | |
| SCHEMBL4847155 | 0.84 | HPGDS (0.43) | MAPK13RAF1MAPK12MAPK11MAPK14 | |
| SCHEMBL528246 | 0.84 | MEN1 (0.46) | KDM4ESMN1; SMN2IDO1GAA | |
| SCHEMBL12590931 | 0.80 | CHEK1 (0.46) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4972272 | 0.79 | PTGS2 (0.48) | MAPK13RAF1MAPK12MAPK11MAPK14 | |
| SCHEMBL7144815 | 0.78 | NR1H2 (0.51) | ALDH1A3KDM4ESMN1; SMN2TSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | claimed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | claimed |
| EP-0996443-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 2000-05-03 | — | — | EP | claimed |
| WO-1999001128-A1 | CERTAIN DIARYLIMIDAZOLE DERIVATIVES; A NEW CLASS OF NPY SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-01-14 | — | — | WO | claimed |
| US-8455528-B2 | Imidazole derivatives useful as inhibitors of FAAH | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110269769-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK SHARP & DOHME CORP. | 2011-11-03 | — | — | US | disclosed |
| EP-2300438-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | Merck Sharp & Dohme Corp. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009152025-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| US-6515133-B1 | Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. | NEUROGEN CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-6121260-A | Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives | NEUROGEN CORPORATION (US) | 2000-09-19 | — | — | US | disclosed |
| CN-1265033-A | Certain diarylimidaozle derivatives, new class of NPY speific ligands | NEUROGEN CORP (US) | 2000-08-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269769-A1 | IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH | FAAH, FAAH2, HNMT | MAPK13 2798/4885RAF1 1747/4885MAPK12 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.